Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 234

1.

Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis.

Fornoni A, Sageshima J, Wei C, Merscher-Gomez S, Aguillon-Prada R, Jauregui AN, Li J, Mattiazzi A, Ciancio G, Chen L, Zilleruelo G, Abitbol C, Chandar J, Seeherunvong W, Ricordi C, Ikehata M, Rastaldi MP, Reiser J, Burke GW 3rd.

Sci Transl Med. 2011 Jun 1;3(85):85ra46. doi: 10.1126/scitranslmed.3002231.

2.

Rituximab's new therapeutic target: the podocyte actin cytoskeleton.

Chan AC.

Sci Transl Med. 2011 Jun 1;3(85):85ps21. doi: 10.1126/scitranslmed.3002429.

PMID:
21632983
3.

Rituximab treatment prevents the early development of proteinuria following pig-to-baboon xeno-kidney transplantation.

Tasaki M, Shimizu A, Hanekamp I, Torabi R, Villani V, Yamada K.

J Am Soc Nephrol. 2014 Apr;25(4):737-44. doi: 10.1681/ASN.2013040363. Epub 2014 Jan 23.

4.

Rituximab protects podocytes and exerts anti-proteinuric effects in rat adriamycin-induced nephropathy independent of B-lymphocytes.

Takahashi Y, Ikezumi Y, Saitoh A.

Nephrology (Carlton). 2017 Jan;22(1):49-57. doi: 10.1111/nep.12737.

PMID:
26833819
5.

Novel unbiased assay for circulating podocyte-toxic factors associated with recurrent focal segmental glomerulosclerosis.

Kachurina N, Chung CF, Benderoff E, Babayeva S, Bitzan M, Goodyer P, Kitzler T, Matar D, Cybulsky AV, Alachkar N, Torban E.

Am J Physiol Renal Physiol. 2016 May 15;310(10):F1148-56. doi: 10.1152/ajprenal.00349.2015. Epub 2015 Dec 30.

6.

Fatal late-onset Pneumocystis pneumonia after rituximab: administration for posttransplantation recurrence of focal segmental glomerulosclerosis--case report.

Dęborska-Materkowska D, Kozińska-Przybył O, Mikaszewska-Sokolewicz M, Durlik M.

Transplant Proc. 2014 Oct;46(8):2908-11. doi: 10.1016/j.transproceed.2014.09.010.

PMID:
25380948
7.

Podocyte foot process effacement in postreperfusion allograft biopsies correlates with early recurrence of proteinuria in focal segmental glomerulosclerosis.

Chang JW, Pardo V, Sageshima J, Chen L, Tsai HL, Reiser J, Wei C, Ciancio G, Burke GW 3rd, Fornoni A.

Transplantation. 2012 Jun 27;93(12):1238-44. doi: 10.1097/TP.0b013e318250234a.

8.

Podocyte effacement closely links to suPAR levels at time of posttransplantation focal segmental glomerulosclerosis occurrence and improves with therapy.

Alachkar N, Wei C, Arend LJ, Jackson AM, Racusen LC, Fornoni A, Burke G, Rabb H, Kakkad K, Reiser J, Estrella MM.

Transplantation. 2013 Oct 15;96(7):649-56. doi: 10.1097/TP.0b013e31829eda4f.

9.

Combination treatment with plasmapheresis and rituximab for recurrent focal segmental glomerulosclerosis after renal transplantation.

Tsagalis G, Psimenou E, Nakopoulou L, Laggouranis A.

Artif Organs. 2011 Apr;35(4):420-5. doi: 10.1111/j.1525-1594.2010.01068.x.

PMID:
20637013
10.

TNFα pathway blockade ameliorates toxic effects of FSGS plasma on podocyte cytoskeleton and β3 integrin activation.

Bitzan M, Babayeva S, Vasudevan A, Goodyer P, Torban E.

Pediatr Nephrol. 2012 Dec;27(12):2217-26. doi: 10.1007/s00467-012-2163-3. Epub 2012 Apr 27.

PMID:
22538781
11.

Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome.

Ravani P, Ponticelli A, Siciliano C, Fornoni A, Magnasco A, Sica F, Bodria M, Caridi G, Wei C, Belingheri M, Ghio L, Merscher-Gomez S, Edefonti A, Pasini A, Montini G, Murtas C, Wang X, Muruve D, Vaglio A, Martorana D, Pani A, Scolari F, Reiser J, Ghiggeri GM.

Kidney Int. 2013 Nov;84(5):1025-33. doi: 10.1038/ki.2013.211. Epub 2013 Jun 5.

12.

Rituximab in post-transplant pediatric recurrent focal segmental glomerulosclerosis.

Kumar J, Shatat IF, Skversky AL, Woroniecki RP, Del Rio M, Perelstein EM, Johnson VL, Mahesh S.

Pediatr Nephrol. 2013 Feb;28(2):333-8. doi: 10.1007/s00467-012-2314-6. Epub 2012 Oct 4.

13.

Successful treatment of recurrent focal segmental glomerulosclerosis with a low dose rituximab in a kidney transplant recipient.

Cho JH, Lee JH, Park GY, Lim JH, Kim JS, Kang YJ, Kwon O, Choi JY, Park SH, Kim YL, Kim HK, Huh S, Kim CD.

Ren Fail. 2014 May;36(4):623-6. doi: 10.3109/0886022X.2014.882238. Epub 2014 Feb 6.

PMID:
24502587
14.

Sphingomyelinase-like phosphodiesterase 3b expression levels determine podocyte injury phenotypes in glomerular disease.

Yoo TH, Pedigo CE, Guzman J, Correa-Medina M, Wei C, Villarreal R, Mitrofanova A, Leclercq F, Faul C, Li J, Kretzler M, Nelson RG, Lehto M, Forsblom C, Groop PH, Reiser J, Burke GW, Fornoni A, Merscher S.

J Am Soc Nephrol. 2015 Jan;26(1):133-47. doi: 10.1681/ASN.2013111213. Epub 2014 Jun 12.

15.

Plasma from a case of recurrent idiopathic FSGS perturbs non-muscle myosin IIA (MYH9 protein) in human podocytes.

Babayeva S, Miller M, Zilber Y, El Kares R, Bernard C, Bitzan M, Goodyer P, Torban E.

Pediatr Nephrol. 2011 Jul;26(7):1071-81. doi: 10.1007/s00467-011-1831-z. Epub 2011 Mar 6.

PMID:
21380797
16.

Rituximab and chronic plasmapheresis therapy of nephrotic syndrome in renal transplantation patients with recurrent focal segmental glomerulosclerosis.

Rodríguez-Ferrero M, Ampuero J, Anaya F.

Transplant Proc. 2009 Jul-Aug;41(6):2406-8. doi: 10.1016/j.transproceed.2009.06.044.

PMID:
19715934
17.
18.

Podocyte expression of nonmuscle myosin heavy chain-IIA decreases in idiopathic nephrotic syndrome, especially in focal segmental glomerulosclerosis.

Miura K, Kurihara H, Horita S, Chikamoto H, Hattori M, Harita Y, Tsurumi H, Kajiho Y, Sawada Y, Sasaki S, Igarashi T, Kunishima S, Sekine T.

Nephrol Dial Transplant. 2013 Dec;28(12):2993-3003. doi: 10.1093/ndt/gft350. Epub 2013 Sep 15.

PMID:
24042022
19.

Increase of integrin-linked kinase activity in cultured podocytes upon stimulation with plasma from patients with recurrent FSGS.

Hattori M, Akioka Y, Chikamoto H, Kobayashi N, Tsuchiya K, Shimizu M, Kagami S, Tsukaguchi H.

Am J Transplant. 2008 Jul;8(7):1550-6. doi: 10.1111/j.1600-6143.2008.02287.x.

20.

Recent progress in the pathophysiology and treatment of FSGS recurrence.

Cravedi P, Kopp JB, Remuzzi G.

Am J Transplant. 2013 Feb;13(2):266-74. doi: 10.1111/ajt.12045. Epub 2013 Jan 11. Review.

Supplemental Content

Support Center